Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales

Vandana Singh
2 min read
0
In this article:

  • Edwards Lifesciences Corp (NYSE: EW) posted a Q1 adjusted EPS of Q1 adjusted EPS of $0.60.60, compared to $0.54 posted a year ago and beating the consensus of $0.57.

  • Sales increased 10% to $1.34 billion (underlying 13%), beating the consensus of $1.31 billion.

  • Transcatheter aortic valve replacement sales grew to $881 million, up 11%. Globally, the company's average selling price and market position were stable.

  • Related: FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery.

  • U.S. TAVR sales grew approximately 10%, and adoption was broad-based across hospitals.

  • TAVR sales outside the U.S. grew about 20% Y/Y.

  • EW held cash and equivalents of $1.5 billion as of March 31, 2022.

  • Guidance: Edwards Lifesciences reaffirmed its FY22 projection of adjusted EPS of $2.50 - $2.65 (consensus of $2.55) and reiterated its top-line outlook of $5.5 billion - $6.0 billion (consensus $5.76 billion).

  • For Q2 FY22, Edwards Lifesciences expects revenue of $1.36 billion - $1.44 billion (consensus $1.46 billion) and adjusted EPS of $0.61 - $0.69 (consensus $0.65).

  • Analyst Reaction: SVB Leerink analyst Danielle Antalffy maintained an Outperform but lowered the price target from $145 to $138.

  • RBC Capital analyst Shagun Singh maintained an Outperform and lowered the price target from $142 to $135.

  • Raymond James analyst Jayson Bedford maintained an Outperform and reduced the price target from $126 to $124.

  • Price Action: EW shares traded 3.67% lower at $112.00 during pre-market trading on Wednesday.

Latest Ratings for EW

Feb 2022

UBS

Upgrades

Neutral

Buy

Jan 2022

Morgan Stanley

Maintains

Overweight

Jan 2022

Raymond James

Maintains

Outperform

View More Analyst Ratings for EW

View more earnings on EW

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories